Background: Al is a veteran of the pharmaceutical industry with nearly 40 years of leadership experience in bringing new therapies to the market and readying pharmaceutical manufacturing facilities for commercial production at both well-established and startup companies. Al brings a deep knowledge and insight into pharmaceutical manufacturing across many dosage forms and manufacturing operations. He is the Co-founder, President, & CEO at ZS Pharma. ZS Pharma was acquired by Astra Zeneca in 2015 for $2.7 billion. At Adams Respiratory Therapeutics, Al along with other team members, brought the Mucinex product line to the market. The company later was acquired by Reckitt Benckiser for $2.3 billion in 2007. Al held senior positions at Genzyme/Bone Care, Wyeth, Boeringher Ingelheim, and Medeva Americas.
Background: Jeff is a veteran of the pharmaceutical industry with 40 years of leadership experience in developing and commercializing new medical therapies. He has invented products leading to significant improvements in patient care and has numerous patents issued by the USPTO in healthcare. He has a track record of success in developing new companies from start-up, through IPO and M&A exits. He is the co-founder and COO at ZS Pharma, acquired by Astra Zeneca in 2015 for $2.7 billion. He is the inventor of the Mucinex product line for Adams Respiratory Therapeutics. He developed and executed the R&D and Regulatory strategy as VP of Development and Regulatory Affairs, which subsequently was acquired by Reckitt Benckiser for $2.3 billion in 2007. Jeff held senior positions at Encysive Pharmaceuticals, Medeva Americas, Marion Merrell Dow and Abbott Laboratories. He is currently serving as the Chairman of the Board for Lantern Pharma.
Background: Alan has been a member of the Board of Directors of Intuitive Surgical, Inc. since February 2000 and has served as the independent lead director from April 2013 to April 2018. Alan was the Founder, Chairman, and Chief Executive Officer of Chrono Therapeutics, a privately held digital medicine company, from February 2014 to February 2018. From 2012 to 2017, he served as a Senior Advisor at Frazier Healthcare Ventures, and also a Venture Partner from 2007 to 2012. Previously, he was the Chief Executive Officer at Incline Therapeutics, Inc., Northstar Neuroscience, and Heartstream, Inc. Alan currently serves as a member of the Board of Directors of several privately held companies and not-for-profit organizations. Dr. Levy earned a B.S. in Chemistry from the City University of New York and a Ph.D. in Organic Chemistry from Purdue University.